🚀 AI-picked stocks soar in May. PRFT is +55%—in just 16 days! Don’t miss June’s top picks.Unlock full list

4D molecular therapeutics CLO sells $259k in stock

Published 04/03/2024, 07:20 PM
FDMT
-

In a recent transaction, Scott Bizily, the Chief Legal Officer (CLO) of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT), sold shares totaling approximately $259,102. The transaction involved the sale of 8,153 shares of common stock at a price of $31.78 each on April 1, 2024. This sale was conducted under a pre-arranged 10b5-1 trading plan, which allows insiders of publicly traded corporations to set up a trading plan for selling stocks they own.

In addition to the sale, Bizily also engaged in multiple transactions to acquire shares through option exercises, with transaction totals for non-derivative securities amounting to $102,224. The prices for these option exercises ranged from $6.49 to $20.24, reflecting the varying strike prices of the stock options Bizily exercised.

The sale and the acquisition of shares by Bizily are part of the standard transactions that executives and insiders of companies carry out, which can be based on various personal financial strategies, including diversification, liquidity needs, or other personal investment considerations.

Following these transactions, Bizily's ownership in 4D Molecular Therapeutics has changed, as reflected in the updated post-transaction amounts. Investors and followers of 4D Molecular Therapeutics often monitor these filings to keep track of insider activities, as they can provide insights into the executives' perspectives on the company's stock value and future performance.

The full details of these transactions are filed with the SEC and are publicly available for review. The company, based in Emeryville, California, operates in the biotechnology industry, focusing on the development of targeted and proprietary therapeutics.

InvestingPro Insights

As 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) navigates through its corporate and financial activities, real-time data from InvestingPro offers a glimpse into the company's current market standing. With a Market Cap of approximately $1.39 billion USD and a striking Revenue Growth of 562.29% in the last twelve months as of Q4 2023, FDMT presents a compelling narrative for investors. Despite these impressive growth figures, the company has experienced a significant 1 Week Price Total Return of -22.16%, indicating recent volatility in its stock price.

InvestingPro Tips highlight that while FDMT holds more cash than debt, suggesting a strong balance sheet, analysts are anticipating both a sales decline and a drop in net income in the current year. The stock has also been noted for its volatility, with a substantial hit over the last week. These factors may be of particular interest to investors who track insider activities, as they could influence the company's stock value and future performance.

For those seeking more in-depth analysis, additional InvestingPro Tips are available, including insights on profitability, asset liquidity, and valuation multiples. With a total of 12 more InvestingPro Tips to explore, investors can gain a comprehensive understanding of 4D Molecular Therapeutics by visiting https://www.investing.com/pro/FDMT. To enhance your research experience, use the coupon code PRONEWS24 to receive an additional 10% off a yearly or biyearly Pro and Pro+ subscription.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.